identify genes conferring resistance to targeted therapeutics, including BRAF and 80 MEK inhibitors, as well as other drugs [5, [7] [8] [9] [10] [11] [12] [13] [14] . Conversely, negative selection 81 CRISPR screens require growing perturbed cells over 10 or more doublings to allow 82 sensitive detection of genes whose knockout leads to moderate fitness defects. 83
Adding a drug interaction necessitates dosing at sub-lethal levels to balance 84 between maintaining cell viability over a long timecourse and inducing drug-gene 85 interactions beyond native drug effects. To our knowledge, a study by Zimmerman 86 et al. [15] and Wang et al. [16] last year, which each used an early version of the 87 software described here, represents the first such efforts in cancer cells. 88 89 Several algorithms currently exist for the analysis of drug-gene interaction 90 experiments [17, 18] . Most rely on adapting methods originally developed for the 91 analysis of RNAseq differential expression data, which is typically characterized by 92 relatively high read counts across genes. High read counts enable the statistically 93 robust detection and ranking of differential expression of genes (in RNA-seq) or 94 abundance of guide RNA (gRNA, in CRISPR screens) using approaches such as the 95 negative binomial P-value model, a trend explored thoroughly in [18] . However, low 96 read counts per gRNA are common in CRISPR data, and are a fundamental feature of 97 genes with fitness defects, leading to a severe loss of sensitivity when applied to 98 Figure 1A) . 157
158
The drugZ algorithm 159 calculates a fold 160 change for each gRNA in an experimental condition relative to an untreated control. 161 A Z-score for each fold change is calculated using an empirical Bayes estimate of the 162 standard deviation, by "borrowing" information from gRNA observed at a similar 163 frequency (read count) in the control cells. Guide-level gene scores are combined 164 into a normalized gene-level Z-scores called normZ, from which P-values are 165 estimated from a normal distribution (Figure 1b) . We used drugZ to calculate 166 normZ scores, P-values, and false discovery rates in SUM149PT breast cancer cells, 167 which carry BRCA1 and TP53 mutations. We also analyzed the same data with four 168 contemporary methods, STARS [7] , MAGeCK [18] , edgeR [20] , and RIGER [21] . We 169 noted that drugZ produced a moderate number of overall hits, relative to other 170 methods, as FDR thresholds were relaxed (Figure 1c) . We evaluated the quality of 171 the hits by measuring their functional coherence. The PARP inhibitor olaparib was 172 developed specifically to exploit the observed synthetic lethal relationship between 173 PARP1 and the BRCA1/BRCA2 genes [22, 23] . Subsequent studies have shown it to 174 be effective against a general deficiency in homologous recombination repair, 175 known as HRD [24] . We therefore calculated the enrichment of each hit set for genes 176 in the DNA damage response (DDR) pathway as annotated in the Reactome database 177 [25] and found that drugZ hits show strong enrichment for DDR genes across a 178 range of FDR thresholds (Figure 1d The drugZ algorithm can also be used to identify suppressor interactions; that is, 186 genes whose perturbation reduces drug efficacy. While BRCA1 mutation is synthetic 187 lethal with PARP1, subsequent mutation of TP53BP1 is associated with acquired 188 resistance to the PARP inhibitor [26] . Drug-gene interactions resulting in positive Z-189 scores reflect such suppressor interactions. Indeed, TP53BP1 is the 8 th -ranked 190 suppressor interaction in BRCA1-deficient SUM149PT cells, with a normZ score of 191 3.05. Similarly, newly described resistance gene C20orf196, now called SHLD1 [27-192 30] , is the top ranked suppressor. Surprisingly, 250 however, the paired-sample approach does not appear to offer significant benefits 251 over an unpaired approach: when calculating fold change as the log ratio of the 252 means of three experimental and three control samples, the results are nearly 253 identical to analysis of three paired samples (Figure 2d-f) . Indeed, treating samples 254 (Figure 3b) . KEAP1 loss-of-function was identified 293 as a modulator of MAP kinase pathway inhibitors in a panel of positive selection 294 screens in multiple cell lines [11] , but EPHX2 is a novel candidate resistance gene. 295
Notably, the ERK inhibitor screens yielded a small number of discrete synthetic and 296 suppressor hits, in contrast with the PARP inhibitor screens, which showed broad 297 interaction across the HR pathway, confirming the general applicability of drugZ in 298 detecting drug-gene interactions. 299
300
We further tested genetic response profile of hTERT-immortalized RPE1 epithelial 301 cells to two commonly used chemotherapeutic drugs, gemcitabine and vincristine, 302 plus HDAC-inhibitor entinostat currently in clinical trials (Figure 4a ). We used our 303 BAGEL pipeline to identify genes whose knockout leads to fitness defect (essential 304 genes; Bayes Factor > 10) or enhanced growth (tumor suppressors, BF < -40) in 305 untreated control cells (Figure 4b ). Each drug reveals synthetic lethal interaction 306 with at least one pathway-specific gene. Entinostat, ostensibly an inhibitor of 307 histone deacetylases HDAC1 and HDAC3, is synthetic lethal with HDAC7 in RPE1 308 cells. Gemcitabine, a pyrimidine nucleoside analog, is synthetic lethal with 309 deoxythymidylate kinase DTYMK. DTYMK phosphorylates dTMP to dTDP, a key step 310 in the synthesis-by-salvage pathway of dTTP [38] . Vincristine, a microtubule 311 stabilizer, is synthetic lethal with CLASP1, a nonmotor microtubule-associated 312 protein that promotes kinetochore-microtubule attachment [39] . Vincristine is 313 further synthetic lethal with drug transporter ABCC1 (multidrug resistance protein 314 MRP1), a known marker of vincristine resistance [40, 41] . 
DrugZ algorithm 395 396
We calculate the log2 fold change of each gRNA in the pool by normalizing the total 397 read count of each sample (to n=10 million reads) at the same timepoint and taking 398 the log ratio, for each replicate, of treated to control reads. 399
Where: 401
• fc = fold change 402
• r = replicate indication 403
• T = treated sample 404
• C = control sample 405
• t = time point 406
• pseudocount = default value is 5 407
408
We estimate the variance of each fold change by calculating the standard deviation 409 of fold changes with similar abundance in the control sample: 410
Where: 412 
458
Equations to update : 459
Where: 461
• n = number of data points (guide Z scores) for each gene 462 The QIAamp Blood Maxi Kit (Qiagen) was used to isolate the genomic DNA (gDNA) 518 from the frozen cell pellets. Guide sequences were enriched using PCR with HiFi 519
HotStart ReadyMix (Kapa Biosystems) and primers targeting the guide region in the 520 genomic DNA. A second round of PCR was performed with i5 and i7 primers to give 521 each condition and replicate a unique multiplexing barcode. The final PCR products 522 were purified using the E-Gel System (Invitrogen), normalized, and sequenced on 523 
